Toleranzia AB has completed a pivotal toxicology study designed to determine the potential toxicity of TOL-2, a tolerance-inducing recombinant protein being developed for the treatment of myasthenia gravis, when given intravenously for 10 days.

Medtronic plc received the greenlight from the U.S. FDA for its latest deep brain stimulation system, the Percept RC. The rechargeable neurostimulator includes the company’s sensing technology which captures data from brain signals and allows for more personalized therapy.

Factor Bioscience Inc. has been awarded a grant by the U.S. Department of Defense to develop next-generation cell therapy candidates using Factor's patented mRNA, cell-reprogramming, and gene-editing technologies.

The first patenting from Mhealthcare Inc. describes a patient examination table or bed equipped with a variety of sensors, data from which may be analyzed with trained machine learning models to facilitate risk assessment and diagnosis of non-neurotypical developmental conditions such as autism in infants and young children by predicting cognitive, behavioral, social and developmental outcomes as early as the first three months of life. It is also claimed that the table may be used to diagnose epilepsy and Alzheimer’s disease.

Researchers from the University of Auckland have developed a smartphone app called Mindear that reduced the impact of tinnitus in two-thirds of users over eight weeks.Tinnitus, often referred to as ringing in the ears, is the perception of sound without an external source and affects 10% to 15% of the global adult population. Previous studies to treat tinnitus have focused on neuromodulation devices, but a smartphone app could make treatment more accessible to a wider population.